These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

495 related items for PubMed ID: 19203907

  • 1. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
    Boffito M, Miralles D, Hill A.
    HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
    [Abstract] [Full Text] [Related]

  • 2. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L.
    AIDS; 2009 Aug 24; 23(13):1679-88. PubMed ID: 19487905
    [Abstract] [Full Text] [Related]

  • 3. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
    Moltó J, Valle M, Santos JR, Mothe B, Miranda C, Cedeño S, Negredo E, Yritia M, Videla S, Barbanoj MJ, Clotet B.
    Antivir Ther; 2010 Aug 24; 15(2):219-25. PubMed ID: 20386077
    [Abstract] [Full Text] [Related]

  • 4. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F.
    HIV Med; 2013 Jan 24; 14(1):49-59. PubMed ID: 23088336
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
    Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wöhrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E, POWER 1 and 2 study groups.
    Lancet; 2007 Apr 07; 369(9568):1169-78. PubMed ID: 17416261
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, Fourie J, De Meyer S, De Pauw M, Lefebvre E, Vangeneugden T, Spinosa-Guzman S.
    AIDS; 2008 Jul 31; 22(12):1389-97. PubMed ID: 18614861
    [Abstract] [Full Text] [Related]

  • 7. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K, Perry CM, Keam SJ.
    Drugs; 2009 Jul 31; 69(4):477-503. PubMed ID: 19323590
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
    Kakuda TN, Brochot A, Tomaka FL, Vangeneugden T, Van De Casteele T, Hoetelmans RM.
    J Antimicrob Chemother; 2014 Oct 31; 69(10):2591-605. PubMed ID: 24951533
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
    Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, Rockstroh J, Stoehr A, Vetter N, Yeni P, Parys W, Vangeneugden T, POWER 1 study group.
    AIDS; 2007 Feb 19; 21(4):395-402. PubMed ID: 17301557
    [Abstract] [Full Text] [Related]

  • 10. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M, Cahn P, Domingo P, Hodder S, Opsomer M, Lathouwers E, Van de Casteele T, Tomaka F.
    HIV Med; 2013 Aug 19; 14(7):437-44. PubMed ID: 23480640
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
    Flynn P, Komar S, Blanche S, Giaquinto C, Noguera-Julian A, Welch S, Lathouwers E, Van de Casteele T, Kakuda TN, Opsomer M.
    Pediatr Infect Dis J; 2014 Sep 19; 33(9):940-5. PubMed ID: 25361024
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
    Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Béthune MP, Tomaka F, De Pauw M, Vangeneugden T, Spinosa-Guzman S, TITAN study group.
    Lancet; 2007 Jul 07; 370(9581):49-58. PubMed ID: 17617272
    [Abstract] [Full Text] [Related]

  • 13. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L, Latch N, Erlwein OW, Mackie NE, Walsh J, Scullard G, McClure MO, Dickinson L, Back D, Winston A.
    Antivir Ther; 2010 Jul 07; 15(2):213-8. PubMed ID: 20386076
    [Abstract] [Full Text] [Related]

  • 14. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
    Cahn P, Fourie J, Grinsztejn B, Hodder S, Molina JM, Ruxrungtham K, Workman C, Van De Casteele T, De Doncker P, Lathouwers E, Tomaka F.
    AIDS; 2011 Apr 24; 25(7):929-39. PubMed ID: 21346512
    [Abstract] [Full Text] [Related]

  • 15. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A, Marcelin AG, Calvez V.
    HIV Med; 2009 Nov 24; 10(10):620-6. PubMed ID: 19601995
    [Abstract] [Full Text] [Related]

  • 16. [Darunavir in treatment-naïve patients. The ARTEMIS study].
    Estrada V, Fuster M.
    Enferm Infecc Microbiol Clin; 2008 Oct 24; 26 Suppl 10():10-3. PubMed ID: 19195454
    [Abstract] [Full Text] [Related]

  • 17. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
    Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L, Fourn E, Duvivier C, Simon A, Courbon E, Murphy R, Flandre P, Peytavin G, Katlama C, RADAR Study Group.
    J Med Virol; 2013 Jan 24; 85(1):8-15. PubMed ID: 23024008
    [Abstract] [Full Text] [Related]

  • 18. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Béthune MP, Picchio G.
    Antivir Ther; 2011 Jan 24; 16(1):99-108. PubMed ID: 21311113
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.
    De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, de Béthune MP, Miralles GD.
    J Acquir Immune Defic Syndr; 2008 Oct 01; 49(2):179-82. PubMed ID: 18769351
    [Abstract] [Full Text] [Related]

  • 20. Darunavir: an effective protease inhibitor for HIV-infected patients.
    Phung BC, Yeni P.
    Expert Rev Anti Infect Ther; 2011 Jun 01; 9(6):631-43. PubMed ID: 21692667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.